Castrate-resistant prostate cancer: postdocetaxel management.

ABSTRACT:

Purpose of review

Prior to 2010, docetaxel was the only treatment shown to prolong survival in metastatic castrate-resistant prostate cancer (CRPC). In the past 3 years, several therapeutic agents have demonstrated survival improvements for CRPC after the receipt of prior docetaxel, leading to multiple approvals by the US Food and Drug Administration.

Recent findings

The development of these novel agents, each with a distinct mechanism of action, is the fruition of sedulous preclinical research and well designed clinical trials. Cabazitaxel, a next generation taxane, was the first Food and Drug Administration-approved drug for the postdocetaxel setting. The recognition of sustained androgen dependence of CRPC has led to the identification of more potent and selective inhibit

SUBMITTER: Zhao S 

PROVIDER: S-EPMC4486479 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature